+ [中微业绩会详聊](https://xueqiu.com/1633174482/337012656)
+ [创新药投资的冰与火之歌](https://xueqiu.com/9742512811/337068656)
+ [2025年伯克希尔·哈撒韦股东大会（第一部分）](https://xueqiu.com/1173786903/337076455)
+ [投研理念｜如何通俗易懂的看懂三张财务报表？](https://xueqiu.com/3199838879/337050641)
+ [为什么你卖出就涨？买入就跌](https://xueqiu.com/2093337947/337055951)
+ [写在成都银行股价即将站上净资产上方之际](https://xueqiu.com/2466842102/337016106)
+ [一文看懂稳定币的背景以及最佳投资方案](https://xueqiu.com/8983534016/337069397)
+ [Summit Therapeutics判断其 PD-1/VEGF 双特异抗体 ivonescimab 是否能获得 美国FDA批准-专业解答](https://xueqiu.com/6540058727/337070020)
+ [国电电力的净利润：扣非还是归母？](https://xueqiu.com/3203323063/336850044)
+ [拼多多25Q1季度跟踪点评](https://xueqiu.com/3452146899/336960020)
+ [再聊聊拼多多](https://xueqiu.com/2103206506/336996822)
+ [关于投资的思考：关于水电的几个核心问题！](https://xueqiu.com/3237139935/336918996)
+ [比亚迪的供应链融资模式能持续下去吗？](https://xueqiu.com/9185767415/336951061)
+ [伊利还是不错的](https://xueqiu.com/2144421443/336917618)
+ [不懂不做](https://xueqiu.com/7913104177/336823258)
+ [拼多多一季度净利润大跌47%的本质原因是什么？](https://xueqiu.com/8809369262/336727530)
+ [标普500：过去，现在和未来](https://xueqiu.com/9808672381/336772288)
+ [红利+微盘: 反转策略姐妹花](https://xueqiu.com/6664428860/336814851)
+ [高分红银行股VS港股高成长科技股，投资者更喜欢那个？](https://xueqiu.com/7271353740/336851313)
+ [投研理念｜没有走不出的周期](https://xueqiu.com/3199838879/336754523)
